Drug
SNX 5422 clinical trials
Also written SNX-5422.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
- SNX-5422
- 10
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 1
Esanex Inc. (12) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses SNX 5422 is read from its arms, and is right about nine times in ten.
Testing it · 13
- Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLLTerminatedPhase 1Esanex Inc.NCT02973399Written as SNX-5422 plus ibrutinib
- Study of SNX-5422 in TP53 Null CancersTerminatedPhase 2Esanex Inc.NCT02612285Written as SNX-5422
- Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine TumorsCompletedPhase 1Esanex Inc.NCT02063958Written as SNX-5422
- Safety and Activity of SNX-5422 Plus Ibrutinib in CLLWithdrawnPhase 1Esanex Inc.NCT02914327Written as SNX-5422 plus ibrutinib
- Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid TumorsCompletedPhase 1Esanex Inc.NCT01892046Written as SNX-5422
- SNX-5422 to Treat Solid Tumor Cancers and LymphomasCompletedPhase 1National Cancer Institute (NCI)NCT00644072Written as SNX-5422
- Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological MalignanciesCompletedPhase 1Esanex Inc.NCT01635712Written as SNX-5422
- Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive CancersTerminatedPhase 1/2Esanex Inc.NCT01848756Written as SNX-5422
- Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung AdenocarcinomaCompletedPhase 1Esanex Inc.NCT01851096Written as SNX-5422
- Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor MalignanciesCompletedPhase 1Esanex Inc.NCT01611623Written as SNX-5422
- Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor MalignanciesCompletedPhase 1Esanex Inc.NCT00506805Written as SNX-5422
- Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological MalignanciesCompletedPhase 1Esanex Inc.NCT00595686Written as SNX-5422
- Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And LymphomasCompletedPhase 1Esanex Inc.NCT00647764Written as SNX-5422 Mesylate Hsp90 inhibitor
Codes
What other systems call SNX 5422 · ClinicalTrials.gg INT005908
- MeSH (NLM) C561943SNX-5422One source NLM
- UNII (FDA) BF52J69Q8TSNX-5422Confirmed FDA, NLM, Wikidata
- Wikidata Q27274626snx-5422Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C141504SNX 5422One source FDA
- DrugBank DB06070One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561943 | SNX-5422 | One source NLM |
| UNII (FDA) | BF52J69Q8T | SNX-5422 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27274626 | snx-5422 | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C141504 | SNX 5422 | One source FDA |
| DrugBank | DB06070 | — | One source Wikidata |
Also registered as snx-5422 mesylate (UNII K3BO8V06RM).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.